2022
Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology
Hrones M, Harigopal M, Xu M, Abi‐Raad R. Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology. Diagnostic Cytopathology 2022, 51: e25-e27. PMID: 36066320, DOI: 10.1002/dc.25052.Peer-Reviewed Original ResearchConceptsBreast implant-associated anaplastic large cell lymphomaImplant-associated anaplastic large cell lymphomaRare T-cell lymphomaAnaplastic large cell lymphomaPeri-implant effusionT-cell lymphomaLarge cell lymphomaCommon presentationDefinite treatmentBetter prognosisCase reportCytopathologic findingsCytopathologic analysisImplant removalEarly diagnosisFluid collectionBreast implantsCytopathological examinationLymphomaReportPatientsPrognosisEffusionDiseaseDiagnosis
2020
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed N. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nature Communications 2020, 11: 3549. PMID: 32669548, PMCID: PMC7363864, DOI: 10.1038/s41467-020-17175-8.Peer-Reviewed Original ResearchConceptsHER2-CAR T cellsCAR T cellsT-cell infusionCAR T-cell infusionT cellsMetastatic rhabdomyosarcomaOngoing phase I trialPhase I trialT cell receptorSecond remissionI trialSerum autoantibodiesImmune reactivityDetectable diseaseTumor responseBone marrowResponse consolidationInfusionRhabdomyosarcomaImmunodominant clonesLymphodepletionRemissionPathway proteinsDiseaseMonths
2009
Clinical trials for pathogen reduction in transfusion medicine: A review
McClaskey J, Xu M, Snyder EL, Tormey CA. Clinical trials for pathogen reduction in transfusion medicine: A review. Transfusion And Apheresis Science 2009, 41: 217-225. PMID: 19793679, DOI: 10.1016/j.transci.2009.09.008.Peer-Reviewed Original ResearchConceptsClinical trialsBlood productsDonor screening programsDonor blood productsRisk of transmissionInfective donorsTransfusion recipientsScreening programClinical settingInfectious diseasesTransfusion medicineTesting regimensPI treatmentTrialsScreening assaysRiskPathogensPotential toxicityPromising strategyDetection of pathogensRegimensPathogen reductionSensitive methodDiseaseRecipients